Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Gains from Sales and Divestitures (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Gains from Sales and Divestitures for 13 consecutive years, with $30211.0 as the latest value for Q1 2026.

  • For Q1 2026, Gains from Sales and Divestitures fell 95.48% year-over-year to $30211.0; the TTM value through Mar 2026 reached $30211.0, down 95.48%, while the annual FY2025 figure was $854220.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures hit $30211.0 in Q1 2026 for Viking Therapeutics, down from $854220.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.6 million in Q3 2024 and bottomed at $30211.0 in Q1 2026.
  • Average Gains from Sales and Divestitures over 5 years is $633221.8, with a median of $668015.0 recorded in 2025.
  • Year-over-year, Gains from Sales and Divestitures surged 262.76% in 2024 and then plummeted 95.99% in 2025.
  • Viking Therapeutics' Gains from Sales and Divestitures stood at $409569.0 in 2022, then surged by 91.69% to $785105.0 in 2023, then skyrocketed by 97.55% to $1.6 million in 2024, then crashed by 44.92% to $854220.0 in 2025, then plummeted by 96.46% to $30211.0 in 2026.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $30211.0, $854220.0, and $62252.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.